Findings of Research Misconduct, 52324 [2015-21354]
Download as PDF
<![CDATA[
52324
Federal Register / Vol. 80, No. 167 / Friday, August 28, 2015 / Notices
Dated: August 14, 2015.
James Macrae,
Acting Administrator, Health Resources and
Services Administration.
Approved: August 17, 2015.
Sylvia M. Burwell,
Secretary.
[FR Doc. 2015–21246 Filed 8–27–15; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Brandi Blaylock, Wake Forest School
of Medicine: Based on an investigation
conducted by Wake Forest School of
Medicine (WFSOM) and additional
analysis conducted by ORI, ORI found
that Ms. Brandi Blaylock, former
Graduate Student, WFSOM, engaged in
research misconduct in research
supported by National Institute of Drug
Abuse (NIDA), National Institutes of
Health (NIH), grant R01 DA012460 and
Ruth L. Kirschstein National Research
Service Award (NRSA) K31 DA033106.
ORI found that Respondent engaged
in research misconduct by falsifying
and/or fabricating data reported in two
poster presentations, several laboratory
meetings, and progress reports
associated with NIDA, NIH, grant R01
DA012460.
Specifically, ORI found that the
Respondent knowingly presented
falsified and/or fabricated data
indicating that twelve non-human
primates (either rhesus or cynomolgus
monkeys) responded to anti-abuse
nicotinic acetylcholine and/or
dopamine receptor selective compounds
in self-selectivity assays for cocaine,
methamphetamines, or nicotine when
the compounds were never given to the
monkeys per protocol.
Respondent has not applied for or
engaged in U.S. Public Health Service
(PHS)-supported research within the
last three (3) years and has stated that
she has no intention of engaging in PHSsupported research in the future.
Ms. Blaylock has entered into a
Voluntary Settlement Agreement and
has voluntarily agreed:
(1) That if within three (3) years from
the effective date of the Agreement,
Respondent receives or applies for PHS
Lhorne on DSK5TPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
14:19 Aug 27, 2015
Jkt 235001
support, Respondent agreed to have her
research supervised for a period of three
(3) years beginning on the date of her
employment in a position in which she
receives or applies for PHS support and
to notify her employer(s)/institution(s)
of the terms of this supervision;
Respondent agreed that prior to the
submission of an application for PHS
support for a research project on which
her participation is proposed and prior
to her participation in any capacity on
PHS-supported research, Respondent
shall ensure that a plan for supervision
of her duties is submitted to ORI for
approval; the supervision plan must be
designed to ensure the scientific
integrity of her research contribution;
Respondent agreed that she shall not
participate in any PHS-supported
research until such a supervision plan is
submitted to and approved by ORI;
Respondent agreed to maintain
responsibility for compliance with the
agreed upon supervision plan;
(2) that if within three (3) years from
the effective date of the Agreement,
Respondent receives or applies for PHS
support, Respondent agreed that for a
period of three (3) years beginning on
the data of her employment in a
position in which she receives or
applies for PHS support, any institution
employing her shall submit in
conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived, and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract; and
(3) to exclude herself voluntarily from
serving in any advisory capacity to PHS
including, but not limited to, service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant for a period of three (3) years,
beginning on August 4, 2015.
FOR FURTHER INFORMATION CONTACT:
Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453–
8200.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2015–21354 Filed 8–27–15; 8:45 am]
BILLING CODE 4150–31–P
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Committee on Vital and Health
Statistics: Meeting
Pursuant to the Federal Advisory
Committee Act, the Department of
Health and Human Services (HHS)
announces the following advisory
committee meeting.
Name: National Committee on Vital
and Health Statistics (NCVHS); Full
Committee Meeting.
Time and Date:
September 16, 2015; 9:00 a.m.–5:30 p.m.
EST.
September 17, 2015; 8:30 a.m.–12:00
p.m. EST.
Place: U.S. Department of Health and
Human Services, Centers for Disease
Control and Prevention, National Center
for Health Statistics, 3311 Toledo Road,
Auditorium A and B, Hyattsville,
Maryland 20782, (301) 458–4524.
Status: Open.
Purpose: The purpose of this meeting
is to review NCVHS Status of Activities,
outline remaining objectives and
deliverables for 2015 and engage in
strategic planning for the next phase of
Committee work. The Committee will
review and coordinate ongoing efforts
being carried out by Subcommittees and
implementing its ACA-designated
Review Committee. Additional topics
will include one action item for
approval: a letter on § 1179 of the
HIPAA statute; and a presentation on
the IOM Report ‘‘Vital Signs: Core
Metrics for Health and Health Care
Progress.’’ The Working Group on HHS
Data Access and Use will continue
strategic discussions on Building a
Framework for Guiding Principles for
Data Access and Use.
The times shown above are for the full
Committee meeting. Subcommittee
issues will be included as part of the
Full Committee schedule.
Contact Person for More Information:
Substantive program information may
be obtained from Rebecca Hines, Acting
Executive Secretary, NCVHS, National
Center for Health Statistics, Centers for
Disease Control and Prevention, 3311
Toledo Road, Room 6316, Hyattsville,
Maryland 20782, telephone (301) 458–
4715. Summaries of meetings and a
roster of committee members are
available on the NCVHS home page of
the HHS Web site: https://
www.ncvhs.hhs.gov/, where further
information including an agenda will be
posted when available.
Should you require reasonable
accommodation, please contact the CDC
Office of Equal Employment
E:\FR\FM\28AUN1.SGM
28AUN1
]]>Agencies
[Federal Register Volume 80, Number 167 (Friday, August 28, 2015)]
[Notices]
[Page 52324]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-21354]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Brandi Blaylock, Wake Forest School of Medicine: Based on an
investigation conducted by Wake Forest School of Medicine (WFSOM) and
additional analysis conducted by ORI, ORI found that Ms. Brandi
Blaylock, former Graduate Student, WFSOM, engaged in research
misconduct in research supported by National Institute of Drug Abuse
(NIDA), National Institutes of Health (NIH), grant R01 DA012460 and
Ruth L. Kirschstein National Research Service Award (NRSA) K31
DA033106.
ORI found that Respondent engaged in research misconduct by
falsifying and/or fabricating data reported in two poster
presentations, several laboratory meetings, and progress reports
associated with NIDA, NIH, grant R01 DA012460.
Specifically, ORI found that the Respondent knowingly presented
falsified and/or fabricated data indicating that twelve non-human
primates (either rhesus or cynomolgus monkeys) responded to anti-abuse
nicotinic acetylcholine and/or dopamine receptor selective compounds in
self-selectivity assays for cocaine, methamphetamines, or nicotine when
the compounds were never given to the monkeys per protocol.
Respondent has not applied for or engaged in U.S. Public Health
Service (PHS)-supported research within the last three (3) years and
has stated that she has no intention of engaging in PHS-supported
research in the future.
Ms. Blaylock has entered into a Voluntary Settlement Agreement and
has voluntarily agreed:
(1) That if within three (3) years from the effective date of the
Agreement, Respondent receives or applies for PHS support, Respondent
agreed to have her research supervised for a period of three (3) years
beginning on the date of her employment in a position in which she
receives or applies for PHS support and to notify her employer(s)/
institution(s) of the terms of this supervision; Respondent agreed that
prior to the submission of an application for PHS support for a
research project on which her participation is proposed and prior to
her participation in any capacity on PHS-supported research, Respondent
shall ensure that a plan for supervision of her duties is submitted to
ORI for approval; the supervision plan must be designed to ensure the
scientific integrity of her research contribution; Respondent agreed
that she shall not participate in any PHS-supported research until such
a supervision plan is submitted to and approved by ORI; Respondent
agreed to maintain responsibility for compliance with the agreed upon
supervision plan;
(2) that if within three (3) years from the effective date of the
Agreement, Respondent receives or applies for PHS support, Respondent
agreed that for a period of three (3) years beginning on the data of
her employment in a position in which she receives or applies for PHS
support, any institution employing her shall submit in conjunction with
each application for PHS funds, or report, manuscript, or abstract
involving PHS-supported research in which Respondent is involved, a
certification to ORI that the data provided by Respondent are based on
actual experiments or are otherwise legitimately derived, and that the
data, procedures, and methodology are accurately reported in the
application, report, manuscript, or abstract; and
(3) to exclude herself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant for a period of three (3) years, beginning on August 4,
2015.
FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240)
453-8200.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2015-21354 Filed 8-27-15; 8:45 am]
BILLING CODE 4150-31-P
